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ABSTRACT
Introduction: Metformin is the most widely administered anti-diabetic medication among
type 2 diabetes mellitus (T2DM) patients. However, metformin induces vitamin B12 malab-
sorption which may increase the risk of vitamin B12 deficiency among T2DM patients. We
determined the prevalence of vitamin B12 deficiency and related risk factors among Ghanaian
T2DM patients on metformin therapy.
Methods: This cross-sectional study recruited 196 T2DM patients attending the outpatient
diabetic clinic at the Effia Nkwanta Regional Hospital, Ghana. Fasting venous blood was
collected for biochemical analysis. Vitamin B12 deficiency was defined as serum B12 <100
pg/ml and methylmalonic acid (MMA) ≥ 0.4µmol/L.
Results: The prevalence of vitamin B12 deficiency based on serum vitamin B12, MMA, and the
combination of both methods were 32.1%, 14.8%, and 14.3%, respectively. Longer duration of
metformin use [5-9 years; aOR= 2.83, 95% CI (1.03-7.81), p=0.045 and ≥10 years; aOR= 4.17,
95% CI (1.41-12.33), p=0.010], higher daily dose of metformin [1000-2000 mg/day; aOR= 1.34,
95% CI (0.25-2.74), p=0.038 and >2000 mg/day; aOR= 1.13, 95% CI (0.39-2.97), p=0.047], and
very high body fat [aOR= 2.98, 95% CI (1.47-6.05), p=0.020] were significantly associated with
increased odds of vitamin B12 deficiency. For daily dose of metformin, a cutoff value of 1500
mg/day presented with a sensitivity, specificity, and AUC of 71.4%, 40.1%, and 0.54 (95% CI,
0.53-0.54), respectively, in predicting vitamin B12 deficiency. A ≥ six (6) years duration of
metformin therapy presented with a sensitivity, specificity, and AUC of 70.4%, 62.9%, and 0.66
(95% CI, 0.57-0.75), respectively, in predicting vitamin B12 deficiency.
Conclusion: Vitamin B12 deficiency is high among T2DM patients on metformin therapy in
Ghana. There is the need for regular monitoring of vitamin B12 levels especially in T2DM
patients on metformin daily dose of ≥ 1500 mg for duration of therapy ≥ 6 years.
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1. Introduction
Diabetes mellitus (DM) is a pervasive chronic meta-
bolic disorder and accounts for up to 90% of all
diagnosed diabetes [1,2]. Type 2 diabetes mellitus
(T2DM) is the most common form of DM, account-
ing for approximately 90% of DM cases [3]. In
Ghana, 6.3% and 6.4% have been quoted as crude
and age-adjusted prevalence of T2DM [4,5]. T2DM is
associated with several detrimental microvascular and
macrovascular complications [6]. As such, effective
management of the disease is crucial.
The American Diabetes Association (ADA) and the
European Association for the Study of Diabetes
(EASD) recommend metformin as the first therapeutic
choice for T2DM management with concurrent life-
style modifications. Reports indicated that metformin
improves peripheral insulin sensitivity and reduces the
risk of cardiovascular mortality in T2DM [7,8] in
addition to its beneficial effects on weight loss and
vascular protection [9]. Nonetheless, as with most
medications, the use of metformin present with some
side effects. Though most of these side effects are mild,
reports indicate that metformin use is associated with
the diminution of the terminal iliac uptake of vitamin
B12 [10,11]. Other studies also report that long-term
use of metformin results in vitamin B12 malabsorption,
with a concomitant reduction in serum vitamin B12
levels [11–13]. Metformin-induced Vitamin B12 defi-
ciency has been reported to be duration of therapy-
and dose-dependent [12].
Metformin-induced vitamin B12 deficiency has also
been associated with neuropathy. The neuropathy asso-
ciatedwith vitamin B12 deficiency ranges fromparesthe-
sia and attenuated peripheral sensation in response to
changes in mental status and proprioception [7] which
overlap with diabetic neuropathy. The progression of
vitamin B12 deficiency-induced neurologic damage can,
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however, be abated through early detection and vitamin
B12 therapy [14]. Nonetheless, if peripheral neuropathy
due to deficiency of vitamin B12 is misconstrued as
diabetic peripheral neuropathy, permanent neurological
damage may occur [15].
Despite the growing evidence of metformin-
induced vitamin B12 deficiency, the prevalence and
association between metformin use and vitamin B12
deficiency in the Ghanaian population is yet to be
elucidated. Furthermore, there are no guidelines to
address how often Ghanaian T2DM patients on met-
formin should be screened for the risk of vitamin B12
deficiency which would inform appropriate prescrip-
tion of vitamin B12 supplements probably due to
limited studies on the subject matter.
Diagnosis of vitamin B12 deficiency can, however, be
difficult. Reports indicate that high serum vitamin B12
levels can be accompanied by signs of deficiency, and
functional deficiency from tissue uptake defects and
action of vitamin B12 at the cellular level have been
implicated in this association [16,17]. Thus, functional
vitamin B12 deficiency can occur regardless elevated
serum B12 levels [17]. As such, a more sensitive screen-
ing method is warranted. One such method exploits
metabolites that accumulate due to vitamin B12 defi-
ciency. Vitamin B12 is involved in the conversion of
methylmalonic acid (MMA) to succinyl-CoA as well
as homocysteine (HC) to methionine in combination
with folic acid [18]. Serum vitamin B12, in combination
with MMA levels, have been demonstrated to be effec-
tive in classifying vitamin B12 deficiency compared to
serum vitamin B12 alone [16,19].
This study, therefore, employed both serum vitamin
B12 and MMA levels to estimate the prevalence of
vitamin B12 deficiency and identify risk factors asso-
ciated with vitamin B12 deficiency among Ghanaian
T2DM patients.
2. Materials and methods
2.1. Study design ∕ setting
This cross-sectional study was conducted at the Diabetic
clinic of the Effia Nkwanta Regional Hospital, Takoradi,
Ghana. Effia Nkwanta Hospital is a referral center for
peripheral health facilities in the Western Region. The
diabetic clinic offers general and specialized care for
diabetes patients.
2.2. Ethical consideration
The study protocol was reviewed and approved by the
Committee for Human Research, Publications and
Ethics of SMS/KNUST/KATH and institutional
approval was obtained from Effia Nkwanta Regional
Hospital. Written informed consent was obtained
from participants after the objectives and benefits of
the study were explained to them. Participation was
entirely voluntary and strict confidentiality of parti-
cipants’ information was maintained throughout the
study.
2.3. Study population
The sample size for this study was calculated using the
Raosoft sample size calculator [20]. At 95% confidence
level, 7%margin of error, and a response distribution of
50%, the minimum sample size for the study was 180
T2DM patients. In an effort to enhance the statistical
power of the study, a total of 250 T2DM patients were
targeted for the study. However, upon excluding sub-
jects who did not fulfill the inclusion criteria, a total of
196 participants were enrolled in the study. Non-
probability sampling technique was employed to recruit
196 consecutive consenting participants who were
already diagnosed of T2DM and on treatment.
Subjects recruitment occurred during patients’ routine
clinic visit. Since T2DM is considered a disease of the
aged, patients aged 35–65 years old, who had been on
metformin, with minimum daily dose of 500 mg, for at
least 6 months were included. T2DM patients who were
pregnant/lactating, alcoholics or drug abuse, known
cases of malabsorption (gastrointestinal surgery,
inflammatory bowel diseases and gluten allergy),
chronic kidney disease, pernicious anemia, thalassae-
mia, sickle cell anemia, consumption of vitamin B12 or
calcium supplementation during the last 3 months and
receiving antibiotics or anymedications known to influ-
ence gastrointestinal motility were excluded from the
study. All relevant clinical data were retrieved from the
hospital’s archive. Participants’ selection protocol is
shown in Figure 1.
2.4. Questionnaire administration
Validated questionnaire was used for data collection.
The questionnaire gathered information on demo-
graphic characteristics, anthropometric variables,
medications (type, dose, and duration) and symp-
toms of neuropathy. Patients information from the
hospital’s archive were cross-referenced to confirm
responses such as medication dose, duration of use,
and duration of diabetes.
2.5. Blood pressure and anthropometric
measurements
Blood pressure was measured from the left upper
arm using a mercury sphygmomanometer and
a stethoscope by a trained nurse at the diabetic
clinic. Participants were asked to rest for at least
5 min before measurement. The average of the two
readings taken 5 min apart was recorded as the
blood pressure measurement.
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Height was measured without wearing shoes using
a wall-mounted ruler, to the nearest 0.1 m. Waist and
hip circumferences were measured to nearest centi-
meter using a measuring tape. Waist to hip ratio
(WHR) = WC (m)/HC (m), waist to height ratio
and (WHtR) = WC (m)/height (m) were calculated
[21]. Total body fat, percentage visceral fat (VF) and
skeletal muscle were also estimated using the Omron
Body Composition Monitor (Omron Corporation,
Japan). Body mass index (BMI) was calculated using
the equation; [BMI (kg/m2) = weight/height2] [22].
2.6. Sample collection, preparation and
biochemical assays
Five millimeters (5 ml) of venous blood sample was
collected after an overnight fast. One (1) milliliter of
blood was dispensed into tubes containing fluoride
oxalate, another 1 ml was dispensed into tubes con-
taining EDTA, and the remaining 3 ml of blood was
dispensed into gel separator tubes. The sample in the
EDTA tube was used for estimation of hemoglobin
(Hb) and glycated hemoglobin (HbA1c) while the
sample in the fluoride oxalate was used for glucose
estimation (FPS). The gel separator tubes were placed
in a centrifuge and span at 3000 rpm for 5 min to
obtain the serum. Hb, HbA1c, and FPS were measured
immediately and the serum for the measurement of
other biochemical variables were stored at −20°C until
analysis. FPS, HbA1c, total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C), triglyceride
(TG), low-density lipoprotein cholesterol (LDL-C),
and calcium were estimated using an automated
chemistry analyzer (Selectra Pro S System, Elitech
Group, France). The estimation of serum vitamin B12
was based on solid-phase Enzyme Linked
Immunosorbent Assay (ELISA) method (standardized
with an intra-assay %CVs = 4.4–5.6% and inter-assay
%CVs = 6.6–7.9%) (MyBioSource, Inc. San Diego, CA,
USA) according to the manufacturer’s instructions.
Briefly, 100 μL of standards, samples and controls
were pipetted into appropriate microtitre wells fol-
lowed by 100 μL of enzyme conjugate reagent, mixed
thoroughly, covered with an adhesive strip, and incu-
bated at 37°C for 60 min. The incubation mixture was
aspirated from the wells followed by five washes with
the wash solution (400 μL). Residual water droplets
were removed by striking the wells onto absorbent
paper. A 50 μL of Substrate A and 50 μL of Substrate
B were pipetted into each well, mixed gently and
incubated at 37°C for 15 min.
The estimation of serum methylmalonic acid was
based on the competitive binding enzyme immunoas-
say technique (standardized with an intra-assay %CVs
<6.1% and inter-assay %CVs <10.2%) (MyBioSource,
Inc. San Diego, CA, USA) according to the manufac-
turer’s instructions. Briefly, 50 μL of standards, controls,
and samples were pipetted into appropriate microtitre
wells which were pre-coated with an antibody specific
to MMA. Fifty microliters (50 μL) of Detection
A working solution was added to each well, mixed
thoroughly, covered with an adhesive strip, and incu-
bated at 37°C for 60 min. The incubation mixture was
aspirated from the wells followed by five washes with
the wash solution (400 μL). Residual water droplets
were removed by striking the wells onto absorbent
paper. A 100 μL of Detection A working solution was
pipetted into each well, mixed gently and incubated at
37°C for 45 min.
Both reactions were stopped by adding 50 μL of
Stop Solution to each well and gently mixed for 30 s.
The absorbance of the final colored product was
measured spectrophotometrically at 450 nm using
Thermo Electron Multiskan EX plate reader
(Shanghai, China). The mean absorbance value
(OD450) for each set of reference standards, controls
Figure 1. Flowchart of the protocol for the selection of subject.
60 M. YAKUBU ET AL.
and samples were calculated. The calculated mean
OD450 obtained for each reference standard were
used to construct a standard curve and the concen-
trations of samples and controls determined from the
standard curve. Vitamin B12 deficiency was defined
by B12 levels <100 pg/mL based on measurement of
serum vitamin B12 and ≥0.4 µmol/L based on MMA
levels [23,24]. Daily calibration and maintenance of
analyzer was performed according to the manufac-
turer’s instructions as previously described [25].
Quality control (QC) was assessed using quality con-
trol materials provided by the manufacturer.
2.7. Statistical analysis
Categorical data were presented as frequencies and
percentages, and Chi-square and Fisher exact test were
used to test for significance of associations where
applicable. Parametric and non-parametric continuous
data were presented as means ± SD and medians (IQR),
respectively, and Independent t-test and Mann
Whitney U test were used to test significance of associa-
tions where applicable. Multivariate logistic regression
model was used to identify risk factors associated with
vitamin B12 deficiency after adjusting for age, sex, over-
weight, anemia, insulin and sulfonylurea use, DM and
medication duration. The covariates selected for the
multivariate regression were known or surmised factors
that could influence vitamin B12 status. The receiver
operating characteristic (ROC) curve was used to deter-
mine the cutoff value of metformin dose and duration
of metformin therapy associated with vitamin B12 defi-
ciency. The optimum cutoff value was determined
based on the highest Youden index [J = (sensitivity +
specificity) – 1]. A ρ value <0.05 was considered statis-
tically significant. Data processing was done using
Microsoft Excel 2016. Statistical analysis and graphical
presentation were performed using the R Language for
Statistical Computing version 3.5.2 (R Core Team,
Vienna, Austria) [26].
3. Results
A total of 196 T2DM patients with mean age of 50.4
(±6.8) years were included in this study. The median
duration of T2DM and metformin therapy was 6.0
(3.0–10.0) years and 5.0 (3.0–8.0) years, respectively.
There were more females (69.9%) than males (30.1%).
The prevalence of anemia based on hemoglobin level
was 45.9% and the average vitamin B12 and MMA
levels among the entire study population were 205.4
pg/ml and 0.07 µmol/L, respectively (Table 1).
The prevalence of vitamin B12 deficiency based on
serum vitamin B12 (sVB12), MMA, and the combina-
tion of both methods (sVB12+ MMA) were 63/196
(32.1%), 29/196 (14.8%), and 28/196 (14.3%), respec-
tively (Figure 2).
There were no statistically significant differences
between the demographic, anthropometric, biochem-
ical parameters and vitamin B12 status (Table 2).
Vitamin B12 deficient subjects presented with sig-
nificantly longer duration of T2DM [10.0 (7.0–11.8)
vs 5.0 (3.0–9.0); p = 0.007] and duration of metfor-
min use [6.0 (4.0–11.0) vs 4.0 (3.0–7.0); p < 0.0001]
compared to non-deficient subjects. Subjects with
vitamin B12 deficiency significantly used higher
doses of metformin (>2000 g/day) compared to non-
deficient subjects (Table 3).
In the multivariate logistic regression, after adjusting
for possible confounding variables, longer duration of
metformin use [5–9 years; aOR = 2.83, 95% CI
(1.03–7.81), p = 0.045 and ≥10 years; aOR = 4.17, 95%
CI (1.41–12.33), p = 0.010], higher daily dose of metfor-
min [1000–2000 mg/day; aOR = 1.34, 95% CI
(0.25–2.74), p = 0.038 and >2000 mg/day; aOR = 1.13,
95% CI (0.39–2.97), p = 0.047], and very high body fat
[aOR = 2.98, 95% CI (1.47–6.05), p = 0.020] were sig-
nificantly associated with increased odds of vitamin B12
deficiency (Table 4).
For daily dose of metformin, a cutoff value of
1500 mg/day presented with a sensitivity, specificity,
and AUC of 71.4%, 40.1%, and 0.54 (95% CI,
0.53–0.54), respectively, in predicting vitamin B12 defi-
ciency. Additionally, ≥ six (6) years duration of
Table 1. Baseline characteristics of entire study subjects.
Variables Mean ± SD
Age (years) 50.4 ± 6.8
Sexa
Male 59 (30.1)
Female 137 (69.9)
Hb (g/dL) 12.2 ± 1.2
Anemic statusa 90 (45.9)
Biochemical Parameters
FPG (mmol/L)b 8.2 (6.5–11.8)
HBA1c (%) 7.1 ± 1.8
TC (mmol/L) 5.2 ± 1.3
TG (mmol/L) 1.7 ± 0.6
HDL-C (mmol/L) 1.2 ± 0.3
LDL-C(mmol/L) 3.7 ± 1.2
Calcium (mmol/L) 2.4 ± 0.2
Vitamin B12 (pg/ml)
b 202.1(132.1–253.8)
MMA (µmol/L)b 0.07(0.01–0.2)
Hemodynamic indices
SBP(mmHg) 137.8 ± 18.7
DBP(mmHg) 83.6 ± 10.6
Anthropometric Indices
BMI (kg/m2) 28.6 ± 5.6
WHR 0.9 ± 0.1
WHtR 0.6 ± 0.1
Visceral fat (%)b 9.5(6.0–14.0)
Body fat (%)b 30.3(24.9–38.0)
Skeletal muscle (%) 28.1 ± 4.7
Duration of DM (years)b 6.0(3.0–10.0)
Duration of metformin therapy (years)b 5.0(3.0–8.0)
Parametric data are presented as mean ± standard deviation, while non-
parametric data presented as median (interquartile range), Hb:
Hemoglobin level, FPG: Fasting Plasma Glucose, HBA1c: Glycated hemoglo-
bin, TC: Total Cholesterol, TG: Triglyceride, HDL-C: High Density Lipoprotein
Cholesterol, LDL-C Low Density Lipoprotein, MMA: Methylmalonic Acid, SBP:
Systolic blood pressure, DBP: Diastolic blood pressure, BMI: Bodymass index,
WHR: Waist–hip ratio, WHtR: waist-to-height ratio. Anemia was defined as
hemoglobin level <12 g/dl for females and 13 g/dl for males.
aPresented as n (%).
‡bPresented as median (interquartile range).
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metformin therapy presented with a sensitivity, specifi-
city, and AUC of 70.4%, 62.9%, and 0.66 (95% CI,
0.57–0.75), respectively, in predicting vitamin B12 defi-
ciency (Figure 3).
4. Discussion
This study reports a high prevalence of vitamin B12
deficiency among Ghanaian T2DM on metformin.
The prevalence of vitamin B12 deficiency based on
serum vitamin B12, MMA, and the combination of
both methods was 32.1%, 14.8%, and 14.3%, respec-
tively. Vitamin B12 deficient subjects presented with
significantly longer duration of T2DM, duration of
metformin use and used higher metformin doses
compared to non-deficient subjects. Using multivari-
ate logistic regression models, after controlling for
multiple potential covariates observed in other
Figure 2. Prevalence of vitamin B12 deficiency among the entire study population.
Table 2. Demographic, anthropometric and biochemical parameters of the study population stratified
by vitamin B12 status.
Vitamin B12 status*
Variables Deficient (n = 28) Non-deficient (n = 168) p-value
Age (years) 51.6 ± 6.5 50.3 ± 6.7 0.328
Sexa 0.278
Male 11(18.3) 49(81.7)
Female 17(12.5) 119(87.5)
Hb (g/dL) 12.1 ± 1.5 12.3 ± 1.3 0.410
Anemic statusa 0.684
Anemic 14(15.7) 75(84.3)
Non-anemic 14(13.2) 92(86.8)
FPG (mmol/L)b 8.7(5.5–12.5) 8.2(6.6–11.6) 0.219
HBA1c (%) 7.2 ± 1.3 7.1 ± 1.9 0.997
TC(mmol/L) 4.9 ± 1.0 5.3 ± 1.3 0.164
TG(mmol/L) 1.6 ± 0.5 1.8 ± 0.6 0.296
HDL-C(mmol/L) 1.1 ± 0.3 1.2 ± 0.3 0.212
LDL-C(mmol/L) 3.5 ± 1.0 3.7 ± 1.2 0.267
Calcium(mg/dL) 2.3 ± 0.5 2.4 ± 0.2 0.066
BMI (kg/m2) 29.9 ± 6.8 28.4 ± 5.4 0.219
WHR 0.9 ± 0.1 0.9 ± 0.1 0.421
WHtR 0.6 ± 0.1 0.6 ± 0.1 0.238
Skeletal muscle (%) 27.2 ± 3.9 28.2 ± 4.8 0.210
Hb: Hemoglobin level, FPG: Fasting Plasma Glucose, HBA1c: Glycated Hemoglobin, TC: Total Cholesterol, TG: Triglyceride,
HDL-C: High-Density Lipoprotein Cholesterol, LDL-C Low-Density Lipoprotein. BMI: Body mass index, WHR: Waist-to-hip
ratio, WHtR: Waist-to-height ratio. Data are presented as mean ± SD unless otherwise specified.
*Based on the prevalence from the combination of serum vitamin B12 and MMA.
aPresented as frequency (%)
bPresented as median (interquartile range)
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studies, we found longer duration of metformin use
(≥5 years), higher daily dose of metformin
(≥1000 mg/day) and very high body fat to be signifi-
cantly associated with increased risk of vitamin B12
deficiency. In determining the optimal cutoff value
for daily dose of metformin and duration of metfor-
min therapy in predicting vitamin B12 deficiency, we
employed the ROC curve analysis. We found metfor-
min dose of 1500 mg/day and ≥six (6) years duration
of metformin therapy to be predictive of vitamin B12
deficiency among the study population.
Varying prevalence rates of vitamin B12 deficiency
amongT2DMpatients onmetformin have been reported
in diverse populations. Report from an early clinical
observational study by Tomkin et al. [27] among Irish
diabetic patients on long-term metformin therapy with
concomitant dietary management indicated a prevalence
of 30% for vitamin B12 malabsorption. DeFronzo et al.
also reported a prevalence of 29% among American
T2DM patients using metformin [28]. Another study by
Sparre Hermann et al. reported a 26.7% prevalence of
vitamin B12 deficiency in metformin-treated T2DM
patients in Sweden [29]. Additionally, a study by
Damião et al. [30] and Pflipsen et al. [23] found a 22.5%
and 22% prevalence of B12 deficiency among Brazilian
andAmericanT2DMpatients usingmetformin.Wulffele
Table 3. Comparison of medication information and symptoms of study participants stratified by vitamin B12
status.
Vitamin B12 status
Variables Deficient (n = 28) Non-deficient (n = 168) p-value
Duration of DM (years)a 10.0(7.0–11.8) 5.0(3.0–9.0) 0.007
Duration of met use (years)a 6.0(4.0–11.0) 4.0(3.0–7.0) <0.0001
Metformin daily doses (mg/day) <0.0001
<1000 4 (14.3) 99(58.9)
1000–2000 6(21.4) 27(16.1)
>2000 18(64.3) 42(25.0)
Metformin +other drugs (Yes, %) 22(78.6) 107(63.7) 0.138
Sign of weakness (Yes, %) 7(25.0) 60(35.7) 0.291
Constipation (Yes, %) 4(14.3) 11(6.5) 0.239
Diarrhea(Yes, %) 1(3.6) 11(6.5) 1.000
Loss of appetite (Yes, %) 0(0.0) 12(7.1) 0.221
Sign of nerve problems (Yes, %) 16(57.1) 104(61.9) 0.607
Gait problem (Yes, %) 5(17.9) 19(11.3) 0.352
Blurred Vision (Yes, %) 16(57.1) 64(38.1) 0.066
Sign of memory loss (Yes, %) 3(10.7) 50(29.8) 0.087
Weight loss (Yes, %) 6(21.4) 64(38.1) 0.085
aPresented as median (interquartile range).
Table 4. Possible risk factors for vitamin B12 deficiency among the study population.
Vitamin B12 deficiency
Variables aOR (95% CI) p-value
Age (per year) 4.12(0.77–21.99) 0.623
Gender (male) 1.5(0.82–2.94) 0.180
BMI (kg∕m2) 1.02(0.96–1.08) 0.464
WHtR 5.68(0.17–189.2) 0.331
WHR 101.9(0.48–2160.9) 0.742
Body Fat
Normal 1
Low 0.82(0.33–2.06) 0.295
High (+) 2.06(0.53–7.97) 0.675
Very High (++) 2.98(1.47–6.05) 0.020
Anemia 4.12(0.77–21.99) 0.098
Medication used
Metformin only 1
Metformin+ Insulin 0.84(0.37–1.93) 0.608
Metformin+ Sulfonylurea 0.73(0.32–1.61) 0.434
Duration of metformin use (years)
<5 1
5–9 2.83(1.03–7.81) 0.045
≥10 4.17(1.41–12.33) 0.010
Metformin daily dose (mg)
<1000 1
1000–2000 1.34(0.25–2.74) 0.038
>2000 1.13(0.39–2.97) 0.047
Duration of DM (years)
<5 1
5–9 1.40(0.41–4.83) 0.591
≥10 4.02(2.06–17.57) 0.072
BMI: Body mass index, WHtR: Waist-to-height ratio, WHR: Waist-to-hip ratio, DM: Diabetes mellitus. Multivariate logistic
regression model was used to identify risk factors associated with vitamin B12 deficiency after adjusting for age, sex,
overweight, anemia, insulin and sulfonylurea use, DM and medication duration. A ρ value < 0.05 was considered statistically
significant (p values of significant variables in bold print).
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et al. also reported a vitamin B12 deficiency prevalence of
about 14% among T2DM patients treated with metfor-
min in the Netherlands [31]. Another study by Ko et al.
reported a 9.5% prevalence of vitamin B12 deficiency in
metformin-treated T2DM patients in Korea [32].
Furthermore, a study by Reinstatler et al. among adults
≥50 years of age from NHANES 1999–2006 found that
biochemical vitaminB12 deficiencywas present in 5.8%of
T2DM patients using metformin and 2.4% among those
not using metformin [33]. Compared to the recent stu-
dies, the alarmingly high prevalence of vitamin B12 defi-
ciency given the conservative cutoff points utilized in this
study is striking. This underscores the need for apt guide-
lines to address how often T2DM patients on metformin
should be screened for the risk of vitamin B12 deficiency
which would inform appropriate prescription of vitamin
B12 supplements. That aside, the discrepancies in preva-
lence rates may be attributed to disparities in the cutoff
values for B12 deficiency, influence of geographical varia-
tions anddietary characteristics. Though themechanisms
underpinningmetformin-induced vitaminB12 deficiency
have not been fully elucidated, bacterial overgrowth in
the small intestine due to DM, changes in the bacterial
flora, alterations in small bowel motility, the inactivation
of vitamin B12 absorption, and the effect of calcium on
cell membranes have been proposed [10,12,27,31].
Clinically, vitamin B12 deficiency has been asso-
ciated with macrocytic anemia, neuropathy, and
mental changes [7,15,34,35]. Thus, though anemia
observed in this study may have multifactorial causes,
vitamin B12 deficiency-associated macrocytic anemia
may be the most probable [34,35]. Importantly also,
the neurologic damage can present as peripheral neu-
ropathy and may be misconstrued for diabetic
neuropathy in patients on metformin therapy [7,15].
Thus, since vitamin B12-associated neuropathy is
reversible, prompt detection and treatment of vitamin
B12 deficiency among T2DM patients on metformin
is crucial to avert permanent neurological damage.
Nonetheless, it is worthy of note that we did not
observe significant association between the manifes-
tations of neuropathy and anemia with vitamin B12
deficiency. A possible reason for this finding may be
due to the direct neuroprotective effect of metformin
through its glucose-lowering effect and antihypergly-
cemic-independent, direct anti-neuropathic impact
on neurons including inhibition of oxidative stress-
related apoptotic cell death [36,37]. Studies by
Ahmed et al. in South Africa and Russo et al. in
Italy [38,39] also found no significant difference in
the presence of neuropathy between subjects with
normal vitamin B12 levels and those with vitamin
B12 deficiency. Additionally, though classical B12 defi-
ciency is associated with clinical symptoms such as
anemia and peripheral neuropathy, these symptoms
are usually absent in those with only biochemical
vitamin B12 deficiency [33]. This may be the reason
for the non-significant association between the vita-
min B12 deficiency and anemia observed in this study.
The association of duration of metformin use and
vitamin B12 deficiency found in this study is expected
as similar findings have been reported by previous
studies. A study by Bauman et al. found that 12 out
of 14 T2DM patients presented with reduced serum
total vitamin B12 levels after 3 months of metformin
therapy [10]. A study by Ting et al. also found
increased duration of metformin use to be associated
with more than two-fold increased risk of developing
Figure 3. Receiver operating characteristic (ROC) curve analysis for the duration and daily dose of metformin in relation to
vitamin B12 deficiency.
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vitamin B12 deficiency [12]. Another study by De Jager
et al. found that the absolute risk of vitamin B12
deficiency after a period of 4 years was 7.2% higher
in T2DM patients on the metformin [40]. A similar
finding has also been reported by Wile and Toth [13],
Wulffelé et al. [31], and Andrès et al. [41]. Despite the
coherence with previous studies, metformin-induced
vitamin B12 deficiency in this study appeared to be
duration of use- and dose-dependent similar to the
findings of Beulens et al. [42]. Ko et al. [32] found
that T2DM patients who had taken metformin
>1,000 mg/day were approximately 10 times as likely
to have vitamin B12 deficiency as patients taking met-
formin ≤1,000 mg/day which is in harmony with this
present study. However, Ko et al. also found that this
dose (>1,000 mg/day) was associated with vitamin B12
deficiency after ≥45.5 months (≈12 years) of therapy
which is a longer period compared to the cutoff pre-
dictive of vitamin B12 deficiency in this study (≥6
years). The longer duration of metformin use may be
due to dissimilarities in the cutoff values of B12 used.
Ko et al. defined vitamin B12 deficiency as serum levels
≤300 pg/mL while we defined vitamin B12 deficiency
as serum levels of both vitamin B12 < 100 pg/mL and
MMA ≥ 0.4µmol/L. The higher cutoff level in their
study may have allowed for the inclusion of more
vitamin B12 deficient subjects with longer duration of
metformin therapy, which may have been missed in
this study, consequently influencing risk associations.
Additionally, the interaction of duration of T2DM and
duration of metformin therapy may be partly involved.
Also of note is the association between vitamin B12
deficiency and very high body fat. A study by Baltaci et al.
[43] reported that obesity based on bioelectric fat analysis
(total body fat %) was significantly associated with vita-
min B12 deficiency which is in harmony with our study
finding. Also consistent with our finding is a study by
Pinhas-Hamiel et al. [44] who reported a greater than
fourfold increased risk of reduced vitamin B12 status in
Israeli obese compared to normal-weight children and
adolescents. Though the mechanisms underpinning the
influence of obesity in vitamin B12 deficiency is still
under investigation, proposed mechanisms include obe-
sity-induced B12 malabsorption, poor dietary content,
repeated short-term restrictive diets and increased
requirements frequently seen in obese people [44–46].
Clinically, however, metformin is frequently prescribed
at higher doses and for longer duration among obese
T2DM patients. Thus, our finding suggests that, a more
frequent assessment of vitamin B12 status for obese
T2DM patients using metformin may have immense
positive influence in abating the high prevalence rate of
metformin-induced vitamin B12 deficiency.
Despite interpreting our results with caution, some
limitation of the study should be acknowledged. One of
which is the cross-sectional design of this study which
precluded the establishment of the causal relation
between metformin and vitamin B12 deficiency. Thus,
case-control or longitudinal studies are required to
prove any causality in this association. The small sample
size is also a limiting factor. Therefore, the findings may
not be generalizable to the general population. The issue
of external validity is also of concern because the study
was conducted in a single urban center and significant
disparities in prevalence rates may exist from in differ-
ent the regions. A follow up using a larger sample size is,
thus, warranted.
5. Conclusion
It was evident from this study that vitamin B12 deficiency
is frequent in Ghanaian T2DM patients on metformin.
The study also confirms findings from other countries
that daily dose and duration of metformin are risk
factors for the development vitamin B12 deficiency.
However, these findings should not be considered as
a basis for discontinuing of the use of metformin in the
treatment of T2DM because metformin has been proven
to produce a better glycemic control in T2DM. Rather,
there is the need for regular monitoring of vitamin B12
levels especially in patients on ≥1500 mg daily dose of
metformin for a duration of six or more years.
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